Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the 8 Most Undervalued Growth Stocks to Buy for the Next 10 Years. On June 16, H.C. Wainwright ******* yst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics Inc. (NASDAQ:HALO) and ******* igned a target price of $95. The stock's potential has been noticed by market participants, as evident from the 46% rise in the last 12 months. With earnings growth expected to continue, HALO is one of our most undervalued growth stocks to buy for the next 10 years.
On a more positive front, on June 13, Johnson & Johnson announced that Halozyme-partnered Darzalex Faspro, when used with its cancer drug Talvey, significantly improved survival outcomes in a late-stage trial for patients with multiple myeloma. The combination reduced the risk of death by up to 53% compared with the standard treatment. Darzalex Faspro is a front-line multiple myeloma therapy. The combination of two drugs, after about two years of follow-up, reduced the risk of cancer worsening or death by up to 72%. Additionally, at 24 months, about 89% of patients were alive, compared with 79% of those receiving standard care. The positive trial results could benefit HALO by supporting continued adoption of Darzalex Faspro, which uses the company's ENHANZE technology.
Halozyme Therapeutics Inc. (NASDAQ:HALO) is a biopharmaceutical company. It researches, develops, and commercializes proprietary enzymes and devices. The company's products are based on the patented recombinant human hyaluronidase enzyme that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules. The company was founded in 1998 and is headquartered in San Diego, California.
While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best AI Stocks to Watch in July and 12 Best Dow Stocks to Invest In Right Now.
On a more positive front, on June 13, Johnson & Johnson announced that Halozyme-partnered Darzalex Faspro, when used with its cancer drug Talvey, significantly improved survival outcomes in a late-stage trial for patients with multiple myeloma. The combination reduced the risk of death by up to 53% compared with the standard treatment. Darzalex Faspro is a front-line multiple myeloma therapy. The combination of two drugs, after about two years of follow-up, reduced the risk of cancer worsening or death by up to 72%. Additionally, at 24 months, about 89% of patients were alive, compared with 79% of those receiving standard care. The positive trial results could benefit HALO by supporting continued adoption of Darzalex Faspro, which uses the company's ENHANZE technology.
Halozyme Therapeutics Inc. (NASDAQ:HALO) is a biopharmaceutical company. It researches, develops, and commercializes proprietary enzymes and devices. The company's products are based on the patented recombinant human hyaluronidase enzyme that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules. The company was founded in 1998 and is headquartered in San Diego, California.
While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best AI Stocks to Watch in July and 12 Best Dow Stocks to Invest In Right Now.
2 months ago
